A Fifth Circuit ruling that keeps mifepristone available, but curtails access to it, is the newest front in a battle over the FDA’s power to approve drugs.
from Feed: All Latest https://ift.tt/VlkXsdf
via IFTTT
from Feed: All Latest https://ift.tt/VlkXsdf
via IFTTT